152608-80-5Relevant academic research and scientific papers
Convenient approach for the synthesis of ONO-LB-457, a potent leukotriene B4 receptor antagonist
Hamri, Salha,Jouha, Jabrane,Oumessaoud, Asmaa,Pujol,Khouili, Mostafa,Guillaumet, Gérald
, (2020/12/07)
This study reports a new approach for the synthesis of 5-[2-(2-carboxyethyl)-3-[6-(4-methoxyphenyl)-(5E)-hexen-1-yloxy]phenoxy]pentanoic acid V (ONO-LB-457), previously described by Konno and col. and which is considered a highly potent and orally active
An efficient method for the synthesis of a novel leukotriene B4 receptor antagonist, ONO-4057, via Michael reaction of dihydroresorcinol
Konno, Mitoshi,Nakae, Takahiko,Sakuyama, Shigeru,Imaki, Katsuhiro,Nakai, Hisao,Hamanaka, Nobuyuki
, p. 1472 - 1474 (2007/10/03)
A practical method for the synthesis of ONO-4057, a highly potent and orally active leukotriene B4 (LTB4) receptor antagonist, was developed. This method includes improved synthesis of a key intermediate, 1,3-dioxo-2-(2-ethoxycarbony lethyl)cyclohexane (6).
Leukotriene antagonists for use in the treatment or prevention of alzheimer's disease
-
, (2008/06/13)
This invention provides methods for the treatment or prevention of Alzheimer's disease which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene antagonist.
Leukotriene-B4 antagonists, process for their production and their use as pharmaceutical agents
-
, (2008/06/13)
The invention relates to leukotriene-B4 antagonists of formula I STR1 in which n represents a whole number from 2 to 5, X represents a direct bond, 1 to 6 methylene units, an ortho-, meta- or para-substituted phenyl ring or a meta- or para-substituted pyridine ring, Y represents a bond to a hydrogen atom and simultaneously to a hydroxy group, a double-bound oxygen atom or --O--CH2 --CH2 --O--, R1 and R2 represent the radical OH, --O--(C1 -C4)--alkyl, O--(C3 -C6)--cycloalkyl, --O--(C6 -C10)--aryl, --O--(C7 -C12)--aralkyl, O--(CH2)--CO-- (C6 -C10)--aryl or the radical NHR3 with R3 meaning hydrogen, (C1 -C4)--alkyl, (C3 -C6)--cycloalkyl or (C7 -C12)--aralkyl as well as their salts with physiologically compatible bases and their cyclodextrin clathrates.
Synthetic and structure/activity studies on acid-substituted 2- arylphenols: Discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist
Sawyer,Bach,Baker,Baldwin,Borromeo,Cockerham,Fleisch,Floreancig,Froelich,Jackson,Marder,Palkowitz,Roman,Saussy Jr.,Schmittling,Silbaugh,Spaethe,Stengel,Sofia
, p. 4411 - 4432 (2007/10/03)
Structural derivatives of LY255283 have been studied as receptor antagonists of leukotriene B4. Substitution of the 2-hydroxyacetophenone subunit of 1 (LY255283) with a 2-arylphenol group provided entry into several new series that feature various mono- and diacidic core functionality. These new analogues, the subject of a broad structure-activity investigation, displayed significantly increased in vitro and in vive activity as receptor antagonists of LTB4. A series of diaryl ether carboxylic acids demonstrated especially interesting activity and led to the discovery of compound 43b, 2- [2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy]- propoxy]phenoxy]benzoic acid (LY293111), a 2-arylphenol-substituted diaryl ether carboxylic acid which displayed potent binding to human neutrophils (IC50 = 17 ± 4.6 nM) and guinea pig lung membranes (IC50 = 6.6 ± 0.71 nM), inhibition of LTB4-induced expression of the CD11b/CD18 receptor on human neutrophils (IC50 = 3.3 ± 0.81 nM), and inhibition of LTB4-induced contraction of guinea pig lung parenchyma (pK(B) = 8.7 ± 0.16). In vivo, 43b demonstrated potent activity in inhibiting LTB4-induced airway obstruction in the guinea pig when dosed by the oral (ED50 = 0.40 mg/kg) or intravenous (ED50 = 0.014 mg/kg) routes. A specific LTB4 receptor antagonist, 43b had little effect on inhibiting contractions of guinea pig lung parenchyma induced by leukotriene D4 (LTD4), histamine, carbachol, or U46619. Compound 43b has been chosen as a clinical candidate and is currently in phase I studies for a variety of inflammatory diseases.
